Gallen International Consensus further emphasized the role of individualized treatment strategies in early HR+/HER2− breast cancer and supported the use of dynamic biomarker changes, such as Ki-67, to guide clinical decision-making. This evidence concerns the gene MKI67 and breast carcinoma.